ESBATech News
Most Popular ESBATech Story
Alcon scoops up ESBATech in $589M buyout
Alcon (ACL) is slapping down $150 million to scoop up Switzerland's ESBATech while setting aside $439 million more for a schedule of milestone payments. For Alcon, the deal delivers antibody fragment Read more...
Latest Headlines
- November 12, 2010
- September 14, 2009
- August 7, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
